ITM Receives Equity Investment of EUR 25 Million
February 17, 20226 min
Investment agreement strengthens the strategic alliance between the two companies while supporting ITM in further developing its radiopharmaceutical pipeline and footprint in Asia Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s Targeted Radionuclide Therapeutic and Diagnostic candidates for Greater China ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Grand Pharmaceutical Group Limited (GP), a diversified global pharmaceutical company listed in Hong Kong, today announced...